x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

OncoPharm

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

science

All Episodes

00:11:48

About Herb Drug Interactions

OncoPharm ·

2025/03/06

Ten of the top herb-chemotherapy interactions.About Herbs website: https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs/search Also, search 'About Herbs' in your app store.

en

00:08:35

Rethinking Premeds

OncoPharm ·

2025/02/27

Two recent publications suggest modifications to standard subcutaneous daratumumab pre-meds is safe...and saves time!Padmaraju et al experience from Chicago Med Center: https://doi.org/10.1093/oncolo/oyae158 Vazirnia et al experience from Mayo Clinic: https://doi.org/10.1200/OP.23.00470 We end summarizing some emerging evidence about the need, or lack thereof, for pre-paclitaxel H2RAs.

en

00:17:25

AMPLIFY

OncoPharm ·

2025/02/20

We take a deep look at the recently published, and guideline changing, AMPLIFY trial of fixed-duration acalabrutinib in CLL.Link: DOI: 10.1056/NEJMoa2409804

en

00:12:35

OncoPharm M & M: Fatal TLS & Fatal T-cell lymphoma...

OncoPharm ·

2025/02/13

Morbidity & Mortality (M & M) are common case conferences to learn from unfortunate cases to improve care in the future. This episode looks at two recently published case reports.1. Fatal tumor lysis syndrome following a lack of venetoclax ramp-up in AML: https://www.jhoponline.com/issue-archive/2024-issues/december-2024-vol-14-no-6/rapid-onset-of-fatal-tumor-lysis-syndrome-in-a-patient-with-acute-myeloid-leukemia-receiving-azacitidine-and-venetoclax-without-a-ramp-up-schedule-a-case-report 2

en

00:18:34

[Re-release] Rituximab

OncoPharm ·

2025/02/06

Dipping into the archives (technology issues with new computer) to re-release the Foundations of OncoPharm episode on rituximab. Where did that 375 mg/m2 dose come from anyway?

en

00:08:47

Acalabrutinb + BR and sotorasib + panitumumab

OncoPharm ·

2025/01/30

FDA approves two new treatment regimens:1. Acalabrutinib + BR for untreated mantle cell lymphoma patients deemed ineligible for autologous HSCT 2. Sotorasib + panitumumab for KRAS-G12C mutated metastatic colorectal cancer (after chemotherapy, including oxaliplatin and irinotecan)

en

00:18:49

Datoptamab deruxtecan

OncoPharm ·

2025/01/22

Datopotamab deruxtecan, a newly approved agent for breast cancer, is discussed.

en

00:12:17

Dex Dosing in MM, Tec-Tal, & postMONARCH

OncoPharm ·

2025/01/16

HOPA Pharmacy Outcomes & Practice-Based Collaboration Survey: https://www.surveymonkey.com/r/MXNVRBRDexamethasone Dosing Intensity in Multiple Myeloma: https://doi.org/10.1182/blood.2024025939 Talquetamab + Teclistamab: https://doi.org/10.1182/blood.2024025939 postMONARCH: https://doi.org/10.1200/JCO-24-02086

en

00:10:52

Breakwater, Ensartinib, & SC Nivo

OncoPharm ·

2025/01/09

We discuss recent approvals of ensartinib and nivolumab-hyaluronidase as well as new front-line option for BRAV-V600E mutated metastatic colorectal cancer.

en

00:13:14

The Accelerated Approval Pathway

OncoPharm ·

2025/01/02

Weighing the Pros & Cons of the accelerated approval pathway as it relates to oncology. An updated draft guidance document from FDA regarding this pathway and some compelling data regarding the public's perceived value of newly approved drugs for cancer.Article: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment. Forest R, et al. Lancet Oncology 2024. Link: https://doi.org/10.1016/S1470-2045(24)00596-5

en

00:18:03

2024 New Drug Review

OncoPharm ·

2024/12/19

Looking back at new approvals from 2024 - what to keep, re-gift, or return?And yes, as soon as this was recorded 2 new drugs were approved.

en

00:17:05

A Feast Of Updates

OncoPharm ·

2024/12/12

Lots of recent clinical trial updates to discuss:AQUILA: Daratumumab for high-risk smoldering multiple myeloma Checkmate 8HW: Nivo/Ipi for MSI-high/MMRd metastatic colorectal cancer DESTINY-Breast06: T-DXd in HER2-low MBC after hormonal treatment, but without previous chemo for MBC ARMANI: Switch maintenance ramucirumab-paclitaxel in metastatic gastric/GEJ cancer HELEN-006: Neoadjuvant nab-paclitaxel/trastuzumab/pertuzumab vs. TCHP in breast cancer SONIA: finally published!

en

00:12:45

Zenocutuzumab

OncoPharm ·

2024/12/05

A first-in-class approval of a bispecific HER2-HER3 monoclonal antibody for NRG1 fusion (+) NSCLC and pancreatic cancer.

en

00:14:52

Revumenib

OncoPharm ·

2024/11/21

The 1st menin inhibitor, revumenib, is approved for relapsed/refractory acute leukemias.Understanding the Pathway: https://doi.org/10.1200/JCO-24-01265

en

00:09:52

Anthracycline Use In Breast Cancer

OncoPharm ·

2024/11/14

A nice editorial succinctly summarizes a framework for thinking about how to incorporate anthracyclines into the treatment of early stage breast cancer patients. Anthracyclines in Early Breast Cancer: The Long Goodbye -https://doi.org/10.1200/JCO-24-01916 10-year Outcomes of READ trial: https://doi.org/10.1200/JCO.24.00836 Bonus - Practical Guide for Testing for Pharmacogenomics: https://doi.org/10.1200/OP.24.00191

en

00:09:18

SWISH

OncoPharm ·

2024/11/07

Reviewing the data to support use of dexamethasone solution mouthwash for PIK3/AKT/mTOR inhibitor-induced stomatitis, caused by drugs like everolimus, alpelisib, capivasertib, & inavolisib.SWISH: https://doi.org/10.1016/s1470-2045(17)30109-2 Alliance MIST Trial: https://doi.org/10.1053/j.seminoncol.2023.01.001

en

00:19:30

Zolbetuximab

OncoPharm ·

2024/10/31

The first Cldn 18.2 targeting monoclonal antibody has been improved. Let's talk about it!

en

00:22:49

S1826 & INTERLACE

OncoPharm ·

2024/10/24

Discussing two excellent articles from earlier this month.S1826: N-AVD vs. Bv-AVD (DOI: 10.1056/NEJMoa2405888) & INTERLACE: induction chemo prior to concurrent cisplatin/RT in locally advanced cervical cancer (DOI: https://doi.org/10.1016/S0140-6736(24)01438-7)

en

00:16:42

Inavolisib

OncoPharm ·

2024/10/17

A new PIK3Ca inhibitor is approved for breast cancer.

en

00:13:48

Autumnal (2024) AML Updates

OncoPharm ·

2024/10/10

Reviewing 3 recent AML publicationsDouble-Dauno (90 mg/m2 vs. 60 mg/m2): https://doi.org/10.1200/JCO.24.00235 AML60+ Risk Stratification: https://doi.org/10.1200/JCO.23.02631 Decitabine-Ven as bridge to Allo HSCT: https://doi.org/10.1016/S2352-3026(24)00241-2

en

409 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter